Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 17, 2024Clinical Pharmacology & Therapeutics

Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis

View Full Paper
Ask AI
Bookmark
Share

Authors

RDRaj DesaiIUIkenna UnigweMRMunaza Riaz

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Desai et al. (2024) studied this question.

synapsesocial.com/papers/68e6ead2b6db6435876663afhttps://doi.org/10.1002/cpt.3271
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative Safety of Long-Acting Versus Short-Acting Erythropoiesis-Stimulating Agents (ESA): Disproportionality Analysis Using the FDA Adverse Event Reporting System2026
  2. 2Comparison of hemoglobin variability between short- and intermediate-acting erythropoiesis-stimulating agents: a retrospective cohort study2026
  3. 3Longer-term Outcomes of Darbepoetin Alfa Versus Epoetin Alfa in Patients With ESRD Initiating Hemodialysis: A Quasi-experimental Cohort Study2015 · 25 citations
  4. 4Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease2010 · 367 citations
  5. 5Short versus long-acting erythropoiesis-stimulating agents for anemia management in Egyptian hemodialysis patients2024